ClinicalTrials.gg
Active, not recruitingNCT07098715Updated Oct 8, 2026

A Study Of Cryptoglandular Fistula-in-ano And Associated Non-healing Draining Wounds With Kerecis SurgiClose

An interventional study of Kerecis fish skin in Fistula-in-ano and Draining Wound, sponsored by Mayo Clinic. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment

How we know

Updated Oct 8, 2026Now Active, not recruitingPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Rectal Fistula with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Rectal Fistula · United States.

Planned enrollment
10th of 15
20 · median 21
Started
2025
with 2 others
No phase
8 of 20
3 open now
Registered
19th of 20
by date
Lead sponsor
2 of 20
Mayo Clinic

Among the 20 studies in Rectal Fistula with a site in United States, this one is the 10th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2025, is one of 8 with no phase, and was the 19th registered.

Rectal Fistula

170 studies on the registry are indexed under Rectal Fistula; 45 are open to participants now.

Browse Rectal Fistula studies →

Open to participants now

7 of the 20 studies in Rectal Fistula with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Rectal Fistula studies recruiting now, 18 (69%) set no upper age limit and 7 (27%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Rectal Fistula with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine feasibility of Kerecis intact fish skin for healing of fistula-in-ano and associated non-healing draining wounds.

03

Conditions studied

  • Fistula-in-ano
  • Draining Wound

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults age ≥18 years old
  • Cryptoglandular fistula-in-ano (primary or recurrent)
  • The ability to give appropriate consent

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years old
  • Pregnant (as determined by urine test)
  • Any known allergies or sensitivities to fish material
  • Prisoners
  • Inflammatory bowel disease
  • Fistula-in-ano associated with:

    • Anal cancer
    • Rectal cancer
    • Extramammary Paget's disease
    • Hidradenitis suppurativa
    • Anal condyloma
    • Active infection / abscess
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Intact Kerecis Fish Skin

    To assess shot-term outcomes (rates of healing) using Kerecis intact fish skin to heal cryptoglandular fistula-in-ano and associated chronic non-healing draining wounds.

    Device: Kerecis fish skin

Interventions

  • DeviceKerecis fish skin

    To assess shot-term outcomes (rates of healing) using Kerecis intact fish skin to heal cryptoglandular fistula-in-ano and associated chronic non-healing draining wounds.

06

What researchers measure

Primary outcomes

  1. Fistula healing

    Assess healing of the fistula. This will be determined based on physical examination. A healed fistula will be a patient who 6 months after surgery no longer has drainage or evidence of infection. The internal opening should be closed on physical exam. The internal opening should feel closed on digital rectal exam. This will be assessed in each patient to determine the overall rate of healing.

    Time frame: From device implant until 6 months after

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Oct 2026, 13 months after the start.

Of 54 non-industry interventional studies with no phase under Rectal Fistula, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 36. This study's planned 13 months is below that.

Counting every sponsor, half of 58 studies reached it within 27 months; a quarter within 11 and three quarters within 38.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 8, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2025
First posted
Aug 1, 2025
StartActual
Sep 11, 2025
Primary completionEst.
Oct 28, 2026was Sep 2026
CompletionEst.
Sep 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Active, not recruiting
changed Oct 8, 2026
Primary completion
Sep 2026→Oct 28, 2026
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Enrolling by invitation→Active, not recruiting
    Primary completion Sep 2026→Oct 28, 2026
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07098715
Lead sponsor
Mayo Clinic
Responsible party
Nicholas P. McKenna (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Aug 1, 2025
Start date
Sep 11, 2025
Primary completion
Oct 28, 2026 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 8, 2026

Study contacts

Nicholas P. McKenna, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion